Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report.
Lung Cancer Manag
; 8(2): LMT10, 2019 Oct.
Article
en En
| MEDLINE
| ID: mdl-31645893
ABSTRACT
A 57-year-old man presented with swelling and pain in the lower limbs, inability to walk and increasing dyspnea for 2 days. Because of refractory stage IV non-small-cell lung cancer, pembrolizumab was started 21 days before presentation. Since then, he experienced general discomfort, fatigue and bilateral weakness in the legs with exercise limitation. A diagnosis of pembrolizumab-induced grade III myositis was made based on muscle biopsy. Pembrolizumab is a humanized monoclonal antibody against PD-1. It has been approved for the treatment of metastatic melanoma and refractory non-small-cell lung cancer with increased expression of PD-L1 on the cell surface of tumor cells. With such a humanized monoclonal antibody, fewer adverse events are expected than with systemic chemotherapy. However, 13% of patients develop autoimmune side effects which can be severe (grade III, IV or V) in 5-10%. We discuss a case of pembrolizumab-induced myositis, with a brief overview of the literature. Only three cases of pembrolizumab-induced myositis have been reported in literature.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
Lung Cancer Manag
Año:
2019
Tipo del documento:
Article
País de afiliación:
Bélgica